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Abstract
A system for sorbent-assisted peritoneal dialysis (SAPD) has been developed that 
continuously recirculates dialysate via a tidal mode using a single-lumen peritoneal 
catheter with the regeneration of spent dialysate by means of sorbents. SAPD treat-
ment may improve plasma clearance by the maintenance of a high plasma-to-di-
alysate concentration gradient and by increasing the mass transfer area coefficient 
(MTAC) of solutes. The system is designed for daily 8-hr treatment (12 kg, night-
time system). A wearable system (2.3 kg, daytime system) may further enhance the 
clearance of phosphate and organic waste solutes during the day. Uremic pigs (n = 3) 
were treated with the day- (n = 3) and nighttime system (n = 15) for 4–8 hr per 
treatment. Plasma clearance (Cl), MTAC, and total mass transport (MT) of urea, 
creatinine, phosphate, and potassium were compared with a static dwell (n = 28). 
Cl, MTAC, and MT of urea, creatinine, phosphate, and potassium were low in the 
pig as compared to humans due to the pig's low peritoneal transport status and could 
be enhanced only to a limited extent by SAPD treatment compared with a static 
dwell (nighttime system: Cl urea: ×1.5 (p = .029), Cl creatinine: ×1.7 (p = .054), Cl 
phosphate: ×1.5 (p = .158), Cl potassium: ×1.6 (p = .011); daytime system: Cl cre-
atinine: ×2.7 (p = .040), Cl phosphate: ×2.2 (p = .039)). Sorbent-assisted peritoneal 
dialysis treatment in a uremic pig model is safe and enhances small solute clearance 
as compared to a static dwell. Future studies in humans or animal species with higher 
peritoneal transport should elucidate whether our SAPD system enhances clearance 
to a clinically relevant extent as compared to conventional PD.
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1 |  INTRODUCTION
Peritoneal dialysis (PD) is a life-sustaining renal replacement 
therapy for patients with end-stage kidney disease (ESKD). 
Although the vast majority (88%) of dialysis patients is treated 
with hemodialysis (HD) (Fresenius Medical Care, 2018), PD 
has several advantages compared with HD. Peritoneal dialysis 
is a blood-free technique that uses relatively simple access to 
the abdomen and can be performed in the home environment. 
It provides more continuous and gradual removal of excess 
water and waste solutes. However, PD has several disadvan-
tages. Clearance is relatively low compared with HD because 
diffusive solute transport rapidly decreases during a dwell 
due to the disappearance of the plasma-to-dialysate concen-
tration gradient across the peritoneal membrane (Bammens, 
Evenepoel, Verbeke, & Vanrenterghem,  2003; Eknoyan 
et  al.,  2002). In addition, technique survival is limited to 
a median of 3.7  years (Mujais & Story,  2006) after which 
patients have to switch to the more invasive and expensive 
HD treatment (Aguirre & Abensur,  2011). Main causes of 
technique failure are recurrent peritonitis (Davenport, 2009) 
and membrane failure (Wu et al., 2012). Both recurrent peri-
tonitis and exposure of the peritoneal membrane to very 
high initial glucose concentrations needed for osmotic fluid 
removal cause pathological changes of the peritoneal mem-
brane (e.g., neoangiogenesis and fibrosis) (Wu et al., 2012) 
and may eventually lead to ultrafiltration failure (Aguirre & 
Abensur, 2011).
Recently, we demonstrated the safety and efficacy of a system 
for sorbent-assisted peritoneal dialysis (SAPD) in vitro (Gelder, 
Simonis, & Monninkof, 2019). The SAPD system comprises a 
wearable sorbent-based device (Figure 1a “the SAPD daytime 
system,” weight: 2.3 kg) that is combined with a dialysate res-
ervoir (provided in a trolley) during the night (Figure 1b “the 
SAPD nighttime system,” weight: 12 kg) to allow for sufficient 
urea and potassium removal. The SAPD nighttime system is 
intended to be used daily for 8  hr per night. Optionally, the 
wearable SAPD system can be used during the day for addi-
tional removal of phosphate and non-urea organic waste sol-
utes. The SAPD system aims to improve uremic toxin removal 
and prolong technique survival compared with conventional PD 
by introducing the following innovations: first, instead of per-
forming 4–6 exchanges per day, only one filling per day is used 
with SAPD treatment that is continuously recirculated and re-
generated by sorbent technology. The continuous flow of fresh 
dialysate along the peritoneal membrane is expected to enhance 
solute removal due to an increase of the mass transfer area co-
efficient (MTAC), as observed with continuous flow-through 
peritoneal dialysis (CFPD) (Cruz et al., 2001; Diaz-Buxo, Cruz, 
& Gotch, 2000; Freida & Issad, 2003; Raaijmakers, Schroder, 
& Gajjar, 2011; Shinaberger, Shear, & Barry, 1965), and main-
tenance of a high plasma-to-dialysate concentration gradient. 
Second, the SAPD system continuously releases glucose at a 
slow and controlled rate, maintaining a relatively constant in-
traperitoneal glucose concentration that is expected to induce 
osmotic fluid removal at a constant rate. In this way, very high 
F I G U R E  1  Schematic representation of the SAPD day- (A) and nighttime system (B). Peritoneal effluent is continuously recirculated via 
a tidal mode into and out of the SAPD system. With the nighttime system, peritoneal effluent first passes the 9-L dialysate reservoir, then the 
sorbents, after which dialysate is temporarily stored in the tidal reservoir until the outflow phase starts and dialysate can be returned into the 
peritoneal cavity. A filter is placed between the sorbents and the peritoneal cavity to prevent particulate matter from entering the peritoneal cavity. 
IN, ingoing line (i.e., dialysate flows into the device); OUT, outgoing line (i.e., dialysate flows out of the device). Pig by Alice Noir from the Noun 
Project
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initial glucose concentrations, as used during conventional PD 
to maintain an osmotic gradient and net fluid removal at the 
end of a dwell, are no longer required. Third, by reducing the 
number of (dis)connections of the peritoneal catheter, SAPD 
treatment may lower peritonitis rates (Fijter et al., 1991).
The aim of the present study was to assess the safety and 
compare the efficacy of the SAPD system in respect to a con-
ventional static dwell (i.e., standard peritoneal permeability 
analysis, SPA) in terms of the MTAC and plasma clearance 
of uremic toxins, and ultrafiltration rate (UFR) in a uremic 
pig model. In addition, acute systemic toxicity was evaluated 
by assessing general clinical condition, electrolyte balance, 
and acid-base balance during treatment.
2 |  METHODS
2.1 | Experimental animal
Three female Yorkshire pigs (Sus scrofa domesticus), weigh-
ing 45–130  kg (bodyweight increased during the study) 
were used, since pigs have a similar bodyweight (and dis-
tribution volume), anatomy and physiology to humans and 
have already been successfully used for the evaluation of 
PD (Roberts & Zaragosa, 2016). Uremia was established by 
subtotal renal artery embolization. Gentamicin (10  mg/kg 
2dd for 7 days) was administered prior to the testing of the 
SAPD system to induce acute-on-chronic kidney injury, re-
sulting in plasma concentrations of uremic toxins in the range 
of those observed in dialysis patients. Peritoneal access was 
established with a straight Tenckhoff PD catheter (Argyle, 
Covidien, Tenckhoff, 1 cuff, 47 cm).
2.2 | Materials
A schematic presentation of the SAPD day- and nighttime 
systems is presented in Figure 1. The sorbent cartridge com-
prises an anion-binder (ferric oxide hydroxide, FeOOH) for 
the removal of phosphate and activated carbon for the removal 
of organic waste solutes (e.g., creatinine). The sorbents were 
equilibrated at [Na+] 132 mmol/L, [Cl−] 97 mmol/L, [lactate] 
10 mmol/L and [HCO3
-] 25 mmol/L at pH 7.0. The dialysate 
reservoir contained Physioneal 35 (Baxter, GmBH Germany) 
glucose 1.36% (n = 7), 1.72% (n = 5) or 2.27% (n = 3) for 
comparison of UFR.
2.3 | Experimental procedures
Three 8-hr experiments with the daytime system (n = 3 ex-
periments in n = 1 pig, Table 1), fifteen 4–8-hr experiments 
with the nighttime system (n = 7, n = 5 and n = 3 per pig, 
Table 2) and 28 SPAs (n = 16, n = 8 and n = 4 per pig), were 
performed in these three pigs for comparison of plasma clear-
ance, MTAC, and total mass transport between SAPD and 
SPA (i.e., static dwell) experiments.
One day prior to SAPD experiments, 2 L of Physioneal 
35 glucose 1.36% (Baxter) or Extraneal 7.5% (Baxter) were 
instilled in the peritoneal cavity to allow for the equilibration 
of blood and PD fluid. A minimum intraperitoneal volume 
of 2 L was required in the pig to achieve a mean effective 
dialysate flow rate (Qd, Formula 1)  >  50  ml/min (i.e., the 
minimum intended flow rate in patients). Prior to start, leu-
kocyte and neutrophil count were measured in the overnight 
dwell and a sample was taken for microbiological culture. At 
the start and end of experiments with the SAPD nighttime 
system, 1 L of fresh PD fluid was instilled to determine in-
traperitoneal volume based on total protein concentration in 
peritoneal effluent before and after the installation of fresh 
PD fluid (Formula 11). Next, the SAPD system was con-
nected to the pig's peritoneal catheter and after the start of 
the dialysate pump, peritoneal effluent was continuously re-
circulated through the SAPD system via a tidal mode, that is, 
alternate in- and efflux of dialysate into- and out of the SAPD 
system, respectively. When catheter outflow obstruction oc-
curred, the pig was sedated with propofol so that it could be 
repositioned to resolve the outflow obstruction.
Venous blood samples were taken from a jugular line be-
fore start and after 2, 4, 6, and 8  hr of treatment for mea-
surement of urea, creatinine, phosphate, potassium, sodium, 
chloride, bicarbonate, calcium, magnesium, albumin, glu-
cose, lactate dehydrogenase, free hemoglobin, hemoglobin, 
leukocyte, and thrombocyte counts and venous blood gas. 
Peritoneal effluent was collected before start and dialysate 
samples were taken from the in- and outgoing line (when 
T A B L E  1  Experimental conditions during the testing of the SAPD daytime system
Experiment
Treatment time 




min) Qd (mL/min) Peritonitis
1 8 200 100 200 67 YES
2 8 300 100 200 67 YES
3 8 300 100 100 50 YES
Mean ± SD 100 ± 0 167 ± 47 61 ± 8
Note: Flow IN, dialysate flow rate into the SAPD system; Flow OUT, dialysate flow rate out of the SAPD system; Qd, mean effective dialysate flow rate.
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dialysate flows into and out of the SAPD system, respec-
tively) after 10 and 30  min, and 1, 2, 3, 4, 6, and 8  hr of 
treatment for measurement of urea, creatinine, phosphate, 
potassium, sodium, chloride, bicarbonate, lactate, calcium, 
magnesium, glucose, osmolality and pH. Thirteen SAPD 
experiments were performed, while the pigs had peritonitis 
(unintentional). Because peritonitis caused a considerable in-
crease in transport status (and MTAC), control experiments 
were also performed during peritonitis (n = 10 SPAs during 
peritonitis, n = 18 SPAs without peritonitis) for comparison.
A veterinarian and experienced biotechnician were 
present during the experiment to monitor the pig's clinical 
conditions.
2.4 | Standard peritoneal 
permeability analysis
The standard peritoneal permeability analysis (SPA) is a tool 
to assess peritoneal membrane permeability characteristics 
which uses a 4-hr dwell with Physioneal 35 1.36% glucose. 
One day prior to the SPA, 2  L of Physioneal 35 glucose 
1.36% or Extraneal 7.5% (Baxter) were instilled in the peri-
toneal cavity, similar to SAPD experiments. The next day, 
a complete drain of the overnight dwell was performed and 
a sample was taken from the drain bag for measurement of 
urea, creatinine, phosphate, glucose, total protein, leuko-
cyte, and neutrophil count. In addition, a sample was taken 
for microbial culture. Subsequently, 2  L of Physioneal 35 
1.36% glucose (n = 26) or 2.27% glucose (n = 2) were in-
stilled and PD effluent samples were collected at 0, 10, 20, 
30, 60, 120, 180, and 240 min for measurement of urea, cre-
atinine, phosphate, glucose and blue dextran. At each time 
point, 100–200 ml of PD effluent was drained into a sterile 
empty dialysate bag, a sample was collected, and the remain-
ing volume was re-instilled. After 240 min, a complete drain 
was performed, followed by rinsing of the peritoneal cavity 
with 1 L of fresh Physioneal 35 (1.36% glucose). Total pro-
tein concentration in the overnight dwell and in the t = 0 min 
sample was used to calculate residual volume at the start of 
the SPA, and total protein concentration in the t = 240 min 
sample and in the drain after flushing at the end of the SPA 
were used to calculate residual volume after the complete 
drain at the end of the SPA (Formula 11). Venous blood sam-
ples were taken at 0, 120, and 240 min for measurement of 
urea, creatinine, and phosphate concentrations.
2.5 | Laboratory measurements
All clinical biochemistry and hematological measurements 
were performed at the hospital laboratory of the UMC 
Utrecht. Urea, creatinine, potassium, phosphate, sodium, 
calcium, magnesium, bicarbonate, lactate, osmolality, al-
bumin, and LDH concentrations were analyzed with a rou-
tine chemistry analyzer (DxAU 5811, Beckman Coulter). 














1 4 300 75 150 50 1.36 YES
2 4 380 150 190 84 1.36 YES
3 6 440 95 190 63 1.36 NO
4 8 300 200 200 100 1.36 YES
5 8 310 165 185 88 1.36 YES
6 8 340 165 170 84 1.36 NO
7 8 340 165 170 84 1.36 NO
8 8 250 160 200 89 1.72 YES
9 8 250 150 190 84 1.72 NO
10 8 250 150 190 84 1.72 YES
11 8 350 155 150 76 1.72 YES
12 8 530 170 160 82 1.72 YES
13 8 280 155 165 81 2.27 NO
14 8 300 155 180 84 2.27 YES
15 8 380 150 190 84 2.27 YES
Mean ± SD 151 ± 29 179 ± 16 81 ± 11
Note: Abbreviations: Flow IN, dialysate flow rate into the SAPD system; Flow OUT, dialysate flow rate out of the SAPD system; Qd, mean effective dialysate flow 
rate.
aGlucose concentration in the dialysate reservoir at the start of treatment. n = 15 experiments were performed in n = 3 pigs (n = 7, n = 5, and n = 3 per pig). 
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Hemoglobin, leukocyte, and thrombocyte concentrations 
were analyzed with a routine hematology analyzer (CELL-
DYN Sapphire, Abbott Diagnostics). Free hemoglobin 
was measured using dual-wavelength spectrophotometry. 
Venous blood gasses were analyzed using a blood gas ana-
lyzer (RAPIDLab type 1265; Siemens Medical Solutions 
Diagnostics B.V.).
2.6 | Calculations and statistics
The mean effective dialysate flow rate during SAPD treat-
ment was calculated as follows:
where Qd = mean effective dialysate flow rate, QIN = dialysate 
flow rate into the system, tIN = time of the inflow phase, and 
tOUT = time of the outflow phase. tIN and tOUT were calculated 
by dividing the tidal volume by QIN and QOUT, respectively.
Peritoneal catheter flow recirculation occurs when di-
alysate returning from the SAPD system into the perito-
neal cavity re-enters the peritoneal catheter when the tidal 
flow changes direction from out- to ingoing. The degree of 
peritoneal catheter flow recirculation (%) was calculated 
based on the creatinine concentration in the peritoneal ef-
fluent sample at t = 8 hr and in the complete drain after 
treatment.
where CR = catheter flow recirculation (%), [creat]t1 = creati-
nine concentration in PD effluent at t = 8 hr, and [creat]t2 = cre-
atinine concentration in the complete drain.
Cumulative removal (or release) by the SAPD system 
from dialysate and plasma clearance was calculated using the 
following formulas:
where A(t1→t2) = amount removed by the SAPD system between 
t1 and t2, DIN  =  dialysate concentration in the ingoing line 
(i.e., upstream of the 10-L reservoir and/or sorbent cartridge), 
DOUT  =  dialysate concentration in the outgoing line (down-
stream of the sorbent cartridge), Qd = mean effective dialysate 
flow rate (L/min) and t = time (min) between two consecutive 
measurements (t2−t1).
where Cl = plasma clearance (mL/min), MTtotal = total mass 
transport, t  =  time (min) between two consecutive measure-
ments, and P = mean plasma concentration calculated as the 
mean of five measurements at t = 0, 2, 4, 6, and 8 hr of SAPD 
treatment.
Total mass transport of solutes (removal or release) from (or 
into) the pig during SAPD experiments was calculated as the sum 
of the cumulative removal (or release) by the SAPD system, the 
amount removed by sampling, and the amount present in the in-
traperitoneal volume at the end of treatment, minus the amount 
present in the intraperitoneal volume at the start of the dwell.
where MTtotal = total mass transport (removal or release) from 
(or into) the pig, A = amount removed (or released) by the SAPD 
system, Asamples = amount removed by sampling, Dt1 = dialy-
sate concentration at t1, Dt2  =  dialysate concentration at t2, 
IPVt1 = intraperitoneal volume at t1 (sum of the filling volume 
and residual volume prior to filling), and IPVt2 = intraperito-
neal volume at the end of treatment (sum of the drained volume 
and residual volume after drainage).
Convective mass transport of waste solutes was calculated 
based on the sieving coefficient, UFR, and the mean solute 
concentration in the peritoneal membrane as described by 
Waniewski, Werynski, Heimburger, and Lindholm (1991).
where MTconvective = convective mass transport, SC = sieving 
coefficient, Cmean = mean concentration in the peritoneal mem-
brane, and t = time between two consecutive measurements.
where Cmean = mean solute concentration in the peritoneal mem-
brane, F = weighing factor (0.5 for small water soluble solutes), 
P = plasma concentration, and D = dialysate concentration.
Diffusive mass transport (Formula 8) was calculated by 
subtracting convective mass transport (Formula 6) from total 
mass transport (Formula 5) as described by Waniewski et al. 
(1991).
where MTdiffusive  =  diffusive mass transport, MTtotal  =  total 
mass transport, MTconvective = convective mass transport.
The MTAC during SAPD experiments was calculated by 



































MTdiffusive (t1→ t2) ∕t
(Pt1−Dt1+Pt2−Dt2) ∕2
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where MTAC  =  mass transfer area coefficient (mL/min), 
MTdiffusive = diffusive mass transport, Pt1 = plasma concen-
tration at t1, Pt2 = plasma concentration at t2, Dt1 = dial-
ysate concentration at t1, Dt2 = dialysate concentration at 
t2, and t  =  time between two consecutive measurements 
(t1−t2).
UFR during SAPD and SPA experiments was calculated 
as follows:
where UFR = ultrafiltration rate, RVt0 = residual intraperitoneal 
volume before the installation of fresh PD solution, RVtx = resid-
ual intraperitoneal volume after the complete drain, Vt0 = vol-
ume of the PD solution bag, Vtx = volume of the complete drain 
bag, Vsamples = total sample volume, and t = dwell time.
Of note, the effective lymphatic adsorption rate (ELAR) 
could not be quantified because no reliable intraperitoneal 
volume marker was available for monitoring the intraperi-
toneal volume during SPA and SAPD experiments, as dex-
tran 70 was not available, use of blue dextran gave unreliable 
results, and albumin stuck to the dialysis membrane of the 
SAPD system. UFR was, therefore, estimated based on the 
intraperitoneal volume at the start and end of the experiment, 
corrected for total sampling volume.
The residual volume before and after SAPD and SPA ex-
periments was calculated based on total protein concentration 
in the peritoneal effluent before and after the installation of 
fresh PD fluid.
where RV  =  residual intraperitoneal volume, Vi  =  volume 
of the instilled (fresh) PD fluid, [total protein]t1 = total pro-
tein concentration in PD effluent before rinsing, and [total 
protein]t2 =  total protein concentration in PD effluent after 
rinsing.
Total mass transport and plasma clearance during SPA 
experiments were calculated using the following formulas:
where MTtotal  =  total mass transport (removal or release) 
from (or into) the pig, Asamples = amount removed by sam-
pling, Dt0 = dialysate concentration at t0, Dt240 = dialysate 
concentration at t = 240 min, IPVt0 = intraperitoneal volume 
at t0 (sum of the filling volume and residual volume prior to 
filling), and IPVt240 = intraperitoneal volume at t = 240 min 
(sum of the drained volume and residual volume after 
drainage).
where Cl  =  plasma clearance (mL/min), MTtotal  =  total 
mass transport (removal or release) from (or into) the pig, 
t = 240 min (= dwell time), and P = mean plasma concentra-
tion calculated as the mean of two measurements before and 
after the SPA.
MTAC urea, creatinine, and phosphate during SPA ex-
periments, were calculated according to Waniewski et al. 
(Krediet, Lindholm, & Rippe, 2000):
where MTAC  =  mass transfer area coefficient, Vm  =  mean 
intraperitoneal volume, t = dwell time, Vt0 = intraperitoneal 
volume at t = 0 min calculated based on total protein con-
centration in the peritoneal effluent before and after the in-
stallation of fresh PD fluid, Vt240 =  intraperitoneal volume 
at t = 240 min, Dt0 = dialysate concentration at t = 0 min, 
Dt240  =  dialysate concentration at t  =  240  min, P  =  mean 
plasma concentration calculated as the mean of two mea-
surements before and after the SPA, and F = weighing fac-
tor which estimates the relative importance of convective 
transport in comparison to diffusive transport (F = 0.5 for 
small, freely diffusible solutes such as urea and creatinine) 
(Waniewski et al., 1991).
Mean electrolyte concentrations, osmolality, and pH in 
the in- and outgoing line of the SAPD system were cal-
culated as a time-weighted mean of nine measurements 
(t = 0, 10, 60, 120, 180, 240, 300, 360, and 480 min) during 
treatment.
A Student's paired t-test was used to compare labo-
ratory measurement before and after treatment and for 
comparison of consecutive SAPD and SPA experiments 
using GraphPad Prism Software (version 8.00; La Jolla, 
California, USA). The mean plasma clearance and MTAC 
per 8-hr SAPD-session were compared with plasma clear-
ance and MTAC during 4-hr SPA experiments. Total mass 
transport during the 8-hr SAPD session was divided by two 
for comparison with a 4-hr SPA. To study the association 
between dialysate flow rate, tidal volume, intraperitoneal 
volume, bodyweight, and the MTAC and plasma clear-
ance of urea, creatinine, and phosphate, univariate linear 
regression was performed using SPSS (version 18; SPSS 
Inc. Headquarters, Chicago, IL, USA). For non-normally 
distributed data, log transformation was applied to allow 
for parametric analysis. Results are expressed as beta 
(β) regression coefficients with p-value. In all statistical 
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3 |  RESULTS
3.1 | Safety analysis
3.1.1 | Treatment tolerance
No signs of abdominal pain or animal discomfort were ob-
served with dialysate flow rates up to 200 ml/min into- and 
out of the peritoneal cavity for 8 hr. No serious adverse events 
occurred that were associated with SAPD treatment.
3.1.2 | Blood measurements
Blood measurements at the start and end of treatment with the 
day- and nighttime experiments are presented in Table 3. Mean 
electrolyte and glucose concentrations, osmolality, and pH in the 
in- and outgoing line of the SAPD system are presented in Table 4.
With the daytime system, plasma calcium concentrations 
tended to decrease as a result of calcium removal by the sor-
bents (2.9  ±  0.6  mmol). Plasma calcium concentrations were 
stable with the nighttime system despite limited calcium release 
(0.34 ± 0.83 mmol) from the dialysate reservoir that contained 
[Ca2+] 1.75  mmol/L. Plasma magnesium concentrations de-
creased with the day- and nighttime systems due to removal by the 
sorbents (1.16 ± 0.28 mmol and 1.74 ± 0.82 mmol, respectively) 
and the relatively low magnesium concentration (0.25 mmol/L) 
in the dialysate reservoir (Physioneal 35). Venous pH increased 
with the day- and nighttime systems due to the combination of 
chloride removal (45.6 ± 8.6 mmol and 9.8 ± 60.5 mmol, respec-
tively) and (limited) base release (Table 6).
3.2 | Efficacy analysis
3.2.1 | Effect of SAPD on plasma clearance, 
MTAC and solute removal
Treatment with the day- and nighttime systems caused an 
increase in plasma clearance and MTAC compared with a 
static dwell (Table 5). A constant high plasma-to-dialysate 
concentration gradient was maintained during the 8-hr SAPD 
treatment (Figure S1). The dialysate-to-plasma concentration 
ratios at 4 hr were lower during SAPD than during SPA ex-
periments (Table S2). Of note, all SPA experiments showed 
a low peritoneal transport status in the pig. The dialysate-
to-plasma concentration ratio for creatinine at 4  hr was 
0.41 ± 0.10 in the absence of peritonitis (“low transporter”), 
compared with 0.78 (0.53–0.98) (“high-average transporter”) 
in humans (Smit et al., 2000).
T A B L E  3  Blood measurements at the start and end of the SAPD day- and nighttime experiments (8 hr per experiment)
Measurement
Nighttime system (n = 15) Daytime system (n = 3)
Start End P* Start End P*
Sodium (mmol/L) 141 ± 0.9 138 ± 3.1 0.189 140 ± 2.2 139 ± 2.6 0.228
Potassium (mmol/L)a 5.2 ± 0.1 4.8 ± 0.5 0.278a 4.1 ± 0.5 3.9 ± 0.5 0.063
Chloride (mmol/L) 106 ± 0.8 100 ± 0.5 0.023 100 ± 5.3 98 ± 4.8 0.009
Calcium (mmol/L) 2.78 ± 0.07 2.58 ± 0.00 0.063 2.61 ± 0.31 2.53 ± 0.14 0.320
Magnesium (mmol/L) 1.20 ± 0.05 1.05 ± 0.07 0.033 1.41 ± 0.36 1.26 ± 0.40 0.057
Bicarbonate (mmol/L) 29.1 ± 1.6 31.4 ± 2.9 0.149 31.3 ± 5.2 31.8 ± 3.8 0.374
Phosphate (mmol/L) 2.40 ± 0.16 2.10 ± 0.22 0.017 2.25 ± 0.31 2.22 ± 0.35 0.325
Urea (mmol/L)a 4.6 ± 2.6 3.9 ± 1.8 0.426a 13.1 ± 6.7 11.8 ± 5.8 0.011
Creatinine (µmol/L) 441 ± 145 386 ± 116 0.120 746 ± 425 732 ± 427 0.404
Albumin (g/L) 24.5 ± 0.9 23.9 ± 1.1 0.096 26.1 ± 7.0 28.3 ± 2.3 0.174
Glucose (mmol/L) 5.8 ± 0.1 6.9 ± 0.3 0.034 5.8 ± 0.9 5.9 ± 0.6 0.928
Lactate dehydrogenase (U/L) 813 ± 79 779 ± 81 0.485 766 ± 362 740 ± 386 0.521
Free hemoglobin (mg/L) 22 ± 11 21 ± 7 0.982 18 ± 10 20 ± 10 0.073
Hemoglobin (mmol/L) 5.4 ± 0.4 6.9 ± 0.3 0.093 5.6 ± 0.5 5.5 ± 0.5 0.220
Thrombocytes (×10^9/L) 310 ± 189 444 ± 87 0.457 383 ± 196 380 ± 176 0.155
Leukocytes (×10^9/L) 13.6 ± 3.9 17.9 ± 3.2 0.423 12.0 ± 3.0 13.4 ± 4.2 0.263
Venous pH 7.39 ± 0.03 7.46 ± 0.01 0.078 7.42 ± 0.06 7.44 ± 0.06 0.037
Note: Data are presented as mean ± standard deviation.
aThe SAPD daytime system does not comprise a urea removal system or cation exchanger for the removal of potassium. n = 15 experiments were performed with the 
nighttime system in n = 3 pigs (n = 7, n = 5, and n = 3 per pig) and n = 3 experiments were performed with the daytime system in n = 1 pig. 
*Statistical significance between end and start was determined using a Student's paired t-test. Significant differences are shown in bold font. 
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3.2.2 | Determinants of the MTAC and 
clearance of urea, creatinine, and phosphate
Dialysate flow rates from the pig into the device of 75 to 200 ml/
min (on average 151 ± 29 ml/min) and from the device to the 
pig of 150 to 200 ml/min (on average 179 ± 16 ml/min) were ap-
plied during experiments with the nighttime system, resulting in 
a mean effective dialysate flow rate of 81 ± 11 ml/min (Table 2). 
At higher flow rates catheter outflow obstruction occurred. Urea 
clearance related positively to mean effective dialysate flow 
rate (β 0.030, p  <  .001), but not to tidal volume, intraperito-
neal volume or bodyweight. No association was observed be-
tween creatinine clearance, phosphate clearance, MTAC urea, 
MTAC creatinine, MTAC phosphate, and dialysate flow rate, 
bodyweight, tidal volume or intraperitoneal volume (Figure S2). 
Mean catheter flow recirculation was 31 ± 11% at a mean effec-
tive dialysate flow rate of 75 ± 14 ml/min.
3.2.3 | Ultrafiltration rate and glucose 
concentrations
Ultrafiltration rate during treatment with the SAPD night-
time system and the SPA experiments was very variable 
(Table  S1) and the lymphatic absorption rate could not be 
determined. Therefore, although maximum intraperitoneal 
glucose concentrations were (not significantly) lower during 
SAPD experiments, no conclusion can be drawn with regard 
to the efficacy of ultrafiltration. Glucose was released by the 
SAPD system at a steady rate, maintaining a relatively con-
stant glucose concentration in the dialysate that is returned 
into the peritoneal cavity (Figure 2).
3.2.4 | Bicarbonate and lactate release
Cumulative bicarbonate and lactate release into the perito-
neal cavity was 7.8  ±  4.1  mmol and 9.3  ±  0.4  mmol, re-
spectively, with the daytime system, resulting in a net buffer 
release of 17.1 mmol. With the nighttime system, cumulative 
bicarbonate removal was 9.3 ± 17.3 mmol and lactate release 
was 30.0 ± 19.2, resulting in net buffer release of 21 mmol 
(Table 4). Of note, the pig's plasma bicarbonate concentration 
at the start of SAPD treatment was high: 29.1 ± 1.6 mmol/L 
and 31.3 ± 5.2 mmol/L with the day- and nighttime systems 
(Table 6), respectively, limiting (daytime system) or prevent-
ing (nighttime system) bicarbonate release.
4 |  DISCUSSION
In the present study, the safety and efficacy of the SAPD sys-
tem, a novel miniature artificial kidney for continuous flow 
peritoneal dialysis, was evaluated in a uremic pig model. 
SAPD treatment was well tolerated and no serious adverse 
events occurred. Plasma clearance of small solutes during 
T A B L E  4  Mean electrolyte concentrations, osmolality, and pH in the SAPD in- (IN) and outgoing (OUT) line during experiments with the 
SAPD day- and nighttime systems
Measurement
Daytime system (n = 3) Nighttime system (n = 15)
Commercial 
PD fluids‡IN OUT P* IN OUT P*
Potassium (mmol/L)a 4.2 ± 0.4 4.1 ± 0.4 <0.001 2.2 ± 0.3 1.6 ± 0.3 <0.001 0
Phosphate (mmol/L) 0.79 ± 0.09 0.57 ± 0.11 0.020 0.30 ± 0.18 0.12 ± 0.08 <0.001 0
Urea (mmol/L)a 3.3 ± 1.4 3.1 ± 1.4 0.057 4.3 ± 2.0 3.1 ± 1.5 <0.001 0
Creatinine (µmol/L) 128 ± 22 52 ± 12 0.029 103 ± 73 39 ± 32 <0.001 0
Sodium (mmol/L) 128 ± 2.9 129 ± 2.9 0.109 127 ± 4.8 128 ± 4.1 0.005 132–134
Chloride (mmol/L) 99 ± 1.0 99 ± 1.2 0.691 98 ± 2.7 98 ± 2.4 0.091 95–105
Bicarbonate (mmol/L) 26.9 ± 0.7 27.2 ± 0.9 0.053 25.8 ± 2.1 25.7 ± 1.6 0.394 0–34
Lactate (mmol/L) 6.2 ± 2.9 6.5 ± 2.8 0.020 8.2 ± 1.6 8.9 ± 1.6 <0.001 0–40
Calcium (mmol/L) 1.25 ± 0.04 1.16 ± 0.05 <0.001 1.34 ± 0.15 1.35 ± 0.15 0.253 1.25–1.75
Magnesium (mmol/L) 0.46 ± 0.02 0.43 ± 0.01 0.184 0.35 ± 0.11 0.30 ± 0.07 0.004 0.25–0.50
Osmolality (mOsmol/kg) 304 ± 3.1 296 ± 3.2 0.024 316 ± 10 311 ± 0.0 0.145 284–483
pH 7.7 ± 0.0 7.8 ± 0.0 0.057 7.6 ± 0.1 7.6 ± 0.1 0.676 5.5–7.4
Note: Data are presented as mean ± standard deviation.
aThe SAPD daytime system does not comprise a urea removal system or cation exchanger for the removal of potassium. ‡Commercial PD fluids include Balance® 
(Fresenius Medical Care, FMC), BicaVera® (FMC), Gambrosol® Trio (FMC), Physioneal® (Baxter), Extraneal® (Baxter), and Nutrineal® (Baxter). n = 15 
experiments were performed with the nighttime system in n = 3 pigs (n = 7, n = 5, and n = 3 per pig) and n = 3 experiments were performed with the daytime system 
in n = 1 pig. 
*Statistical significance between OUT and IN was determined using a Student's paired t-test. Significant differences are shown in bold font. 
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SAPD treatment increased compared with a static dwell. 
Depending on the solute, this could be partly attributed to 
a (limited) increase in MTAC. In addition, maintenance of 
a relatively high plasma-to-dialysate concentration gradient 
contributed to the enhanced clearance.
During SAPD treatment, dialysate is regenerated by means 
of sorbents. Ferric oxide hydroxide is used for the removal 
of anions (primarily phosphate) and activated carbon for the 
removal of organic waste solutes (e.g., creatinine). Since 
the affinity of activated carbon for urea is low (van Gelder, 
Jong, et al., 2020) and the system does not contain a cation 
exchanger, the nighttime system is equipped with a dialysate 
reservoir for (additional) removal of urea and potassium. 
During the experiments with the nighttime system, creatinine 
and phosphate were, indeed, primarily removed via binding to 
the sorbents (80 ± 7% and 75 ± 8% of total removal, respec-
tively) and urea and potassium primarily by the dialysate res-
ervoir (86 ± 11% and 97 ± 8% of total removal, respectively). 
However, total mass transport and solute clearance were low 
in the pig compared to humans and could be enhanced only to 
a limited extent by SAPD treatment. This was primarily due to 
the low peritoneal transport status of the pig (low to low-aver-
age) compared to humans. In comparison, approximately 5% 
of PD patients are low-transporters and 28% are low-aver-
age transporters (Rumpsfeld, McDonald, & Johnson, 2006). 
MTAC of urea, creatinine, and phosphate were 3- to 5-fold 
T A B L E  5  Plasma clearance, mass transfer area coefficient (MTAC), and total mass transport of urea, creatinine, phosphate, and potassium 













Urea NO 5.4 ± 1.6 6.8 ± 1.7 ×1.3 0.051
YES 5.6 ± 1.9 3.4 ± 1.4 ×0.6 0.153a 8.6 ± 3.6 ×1.5 0.029
Creatinine NO 3.4 ± 0.7 3.9 ± 0.5 ×1.2 0.161
YES 4.0 ± 1.6 10.7 ± 2.0 ×2.7 0.040 6.6 ± 3.9 ×1.7 0.054
Phosphate NO 2.7 ± 0.8 3.3 ± 0.8 ×1.2 0.242
YES 3.2 ± 1.5 7.2 ± 1.4 ×2.2 0.053 4.9 ± 3.7 ×1.5 0.158
Potassium NO 7.4 ± 1.3 8.9 ± 1.0 ×1.2 0.023
YES 6.8 ± 1.1 2.9 ± 1.3 ×0.4 0.039a 10.9 ± 3.8 ×1.6 0.011
MTAC (mL/min)
Urea NO 9.5 ± 2.1 11.7 ± 2.8 ×1.2 0.027
YES 13.5 ± 3.8 17.3 ± 6.9 ×1.3 0.827a 15.2 ± 9.4 ×1.1 0.296
Creatinine NO 4.1 ± 1.2 5.0 ± 0.9 ×1.2 0.050
YES 7.3 ± 3.0 16.7 ± 3.3 ×2.3 <0.001 9.1 ± 7.1 ×1.3 0.037
Phosphate NO 3.2 ± 1.1 3.9 ± 1.0 ×1.2 0.077
YES 5.6 ± 2.3 11.0 ± 2.1 ×2.0 0.095 6.6 ± 6.2 ×1.2 0.400
Potassium NO 19.0 ± 2.7 18.6 ± 3.0 ×1.0 0.928
YES 18.8 ± 6.3 16.0 ± 4.1 ×0.9 0.093a 22.8 ± 7.9 ×1.2 0.241
MTtotal (mmol/ 4h)
Ureaa NO 12.6 ± 6.2 21.5 ± 8.1 ×1.7 0.045
YES 16.9 ± 6.5 3.7 ± 2.3 ×0.2 0.015a 18.9 ± 10.8 ×1.1 0.295
Creatinine NO 0.5 ± 0.2 0.7 ± 0.4 ×1.5 0.449
YES 0.7 ± 0.4 1.1 ± 0.4 ×1.5 0.240 0.8 ± 0.5 ×1.2 0.125
Phosphate NO 1.5 ± 0.3 1.7 ± 0.6 ×1.1 0.373
YES 4.0 ± 0.5 ×2.1 0.023 2.2 ± 1.2 ×1.2 0.302
Potassiuma NO 7.2 ± 1.6 8.2 ± 1.1 ×1.1 0.170
YES 6.5 ± 1.5 3.4 ± 1.4 ×0.5 0.044a 9.2 ± 3.7 ×1.4 0.130
Note: MTAC, mass transfer area coefficient; MTtotal, total mass transport; SPA, standard peritoneal permeability analysis.
aThe SAPD daytime system does not comprise a urea removal system or cation exchanger for the removal of potassium. n = 15 experiments were performed with the 
nighttime system in n = 3 pigs (n = 7, n = 5, and n = 3 per pig), n = 3 experiments were performed with the daytime system in n = 1 pig and 28 SPA experiments 
were performed in n = 3 pigs (n = 8, n = 16, and n = 4 per pig). 
*P-value was calculated using a Student's paired t-test for comparison of consecutive SAPD and SPA experiments. 
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lower in the pig than in PD-patients (Clerbaux, Francart, 
Wallemacq, Robert, & Goffin, 2006; Fischbach et al., 2004; 
Teixidó-Planas,  2002). Consequently, solute concentrations 
in peritoneal effluent entering the SAPD system were low, 
accounting for the low absolute removal by the system. Of 
note, in vitro studies showed that in case of higher toxin de-
livery to the system the capacity of the system was sufficient 
to remove the daily toxin production (van Gelder, Ligabue, 
et al., 2020). The increase of the MTAC during SAPD treat-
ment (1.1- to 1.3-fold for urea and 1.2- to 2.3-fold for creat-
inine vs. a static dwell) was lower than previously reported 
in patients treated with CFPD (1.5- to 2.5-fold for urea and 
1.4- to 2.5-fold for creatinine) (Amerling et al., 2001; Cruz 
et al., 2001; Freida & Issad, 2003; Raaijmakers et al., 2011). 
This might also be related to the pig's low peritoneal mem-
brane permeability as patients with higher transport status 
may benefit more from the continuous circulation of the dial-
ysate (Edefonti et al., 1995; Flanigan, Lim, & Pflederer, 1993; 
Holtta, Ronnholm, & Holmberg,  2000; Rodriguez,  1998; 
Vychytil, Lilaj, Schneider, Hörl, & Haag-Weber,  1999) 
than patients with low membrane permeability (Freida & 
Issad, 2003). Indeed, the increase in MTAC of creatinine and 
phosphate was more pronounced during peritonitis, when 
peritoneal transport status was higher. Another explanation 
for the relatively limited increase in clearance in our study as 
compared to CFPD in humans may be that SAPD applies a 
tidal flow rate via a single-lumen catheter, whereas previous 
studies used two separate single-lumen catheters (one for the 
inflow of fresh dialysate and one for outflow, respectively). 
The use of a separate in- and outflow catheter eliminates the 
dead volume (~50 ml with the current system), may reduce 
recirculation (~31% in our study), improve intraperitoneal 
fluid mixing and may optimize the dialysate flow along 
the peritoneal membrane and increase the effective mem-
brane area, which are both crucial for increasing the MTAC 
(Gotch, 2001).
Two other initiatives are known in the field of CFPD with 
sorbent-based dialysate regeneration. First, the automated 
wearable artificial kidney for PD (AWAK PDTM, <2  kg 
(Automated Wearable Artificial Kidney, 2020)) designed by 
AWAK Pte Ltd (Singapore and Burbank, CA) uses a modi-
fied REDY sorbent system, containing urease for enzymatic 
hydrolysis of urea, activated carbon, and ion exchangers for 
dialysate regeneration and, similar to SAPD, a single-lumen 
PD catheter to perform CFPD using a tidal mode with rapid 
cycling of 250 ml of dialysate (mean effective dialysate flow 
rate 33 ml/min). The system is designed for 24-hr use which 
requires three sorbent cartridges per day. In a first-in-human 
clinical trial, 14 PD patients were treated for ≥10.5 hr per 
day for up to three days (Al-Hwiesh et  al., 2019). Prior to 
the replacement of a cartridge, an exchange with 1–2 L of 
fresh dialysate was performed. Plasma concentrations of 
urea, creatinine, and phosphate decreased significantly by 
29%, 31%, and 17%, respectively, indicating that clearance 
increased during treatment with AWAK PD as compared to 
conventional PD that was applied prior to and after AWAK 
PD treatment. However, plasma clearances and MTACs were 
not reported. The second initiative is the Carry Life System 
(CLS) for PD designed by Triomed AB (Lund, Sweden) 
which uses activated carbon and ion-exchangers for dialy-
sate regeneration and a second PD catheter for CFPD with 
continuous recirculation of dialysate. The system requires a 
new sorbent cartridge (<5 kg) every 4 hr. In a first-in-hu-
man clinical trial, five PD patients were treated for eight 
hours. A dialysate flow rate of 17 ml/min was applied and 
urea, creatinine, and phosphate clearances of 10.6  ±  1.9, 
8.1 ± 2.1, and 6.4 ± 1.3 ml/min, respectively, were achieved 
during treatment, which is comparable to the clearances 
achieved during the night with APD (Bammens et al., 2003; 
Paniagua et al., 2002). Thus, findings from these two trials in 
PD patients show that CFPD using sorbent-based dialysate 
regeneration can provide solute clearances that are at least 
F I G U R E  2  Dialysate glucose concentration (%) in the outgoing 
line of the SAPD nighttime system using Physioneal 35 with 1.36%, 
1.72%, and 2.27% glucose in the 10-L reservoir
T A B L E  6  Cumulative removal (or release) of bicarbonate, 















Note: Positive and negative values represent removal and release, respectively. 
A, cumulative removal (or release) by the SAPD system. Glucose release when 
the dialysate reservoir contained glucose *1.36%, †1.72%, and ‡2.27%.
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comparable to conventional PD, also when applying CFPD 
via tidal mode with one single-lumen PD catheter (AWAK 
PD). Both initiatives used dialysate flow rates that were rel-
atively low. An important question remains whether higher 
clearances can be achieved with higher dialysate flow rates, 
as applied with our SAPD system. In contrast to AWAK PD 
and the CLS, our SAPD nighttime system lacks miniatur-
ization (compared to conventional PD). However, our sys-
tem is a low-risk system as opposed to the more complex 
urease-based sorbent system of AWAK PD which needs a 
cation exchanger to bind ammonium formed during enzy-
matic hydrolysis of urea. Also, the CLS contains a cation 
exchanger for the adsorption of potassium. In exchange for 
ammonium and/or potassium, the cation exchangers release 
sodium and hydrogen that must be neutralized to prevent the 
sodium loading of the patient and acidosis, respectively. In 
addition, the cation exchangers remove calcium and magne-
sium ions which need to be replenished, adding to the com-
plexity of the system. Another feature of our SAPD system is 
that the dialysate reservoir (in combination with the increase 
in MTAC due to CFPD) is expected to provide clearance of 
other (not yet identified) “non-bound” uremic waste solutes 
that approaches that of conventional PD.
Although the SAPD system does not comprise a cation 
exchanger, removal of a limited amount of potassium, cal-
cium, and magnesium by the sorbents was observed in vivo 
and in vitro via binding to negatively charged phosphate that 
is bound to FeOOH. Calcium and magnesium removal can, 
therefore, not be prevented by the preloading of the sorbents. 
For the nighttime system, calcium removal was prevented 
by the relatively high calcium concentration in the dialysate 
reservoir (1.75  mmol/L). In theory, increasing magnesium 
concentration in the dialysate reservoir will also prevent 
magnesium removal, but for the current study (unmodi-
fied) commercially available dialysate (Physioneal 35: [Mg] 
0.25 mmol/L) was selected for practical reasons. If necessary, 
magnesium concentration can be increased in the dialysate 
reservoir of the final system.
Treatment with the SAPD day- and nighttime systems re-
sulted in net base release (sum of bicarbonate and lactate) 
into the pig of 17 and 21 mmol, respectively, coinciding with 
an increase in plasma bicarbonate concentration, decrease 
in plasma chloride concentration, and an increase in venous 
pH. However, the total base release was relatively low as 
compared to the average daily nonvolatile acid production in 
humans of ~70 mmol (Scialla, Asplin, & Dobre, 2017). In 
healthy patients, the elimination of this acid load is achieved 
by the urinary excretion of hydrogen ions, both as titratable 
acid and as ammonium (Rose & Post, 2001). ESKD leads to 
the retention of hydrogen ions. To buffer the retained acid 
and prevent metabolic acidosis in ESKD, a base load is de-
livered via the dialysate in conventional dialysis. Base release 
by the SAPD system observed in this study may be too low to 
prevent metabolic acidosis in patients. However, the pigs had 
metabolic alkalosis, which limited bicarbonate release. In ad-
dition, slow equilibration between plasma and intraperitoneal 
compartment in the pig limited lactate release. In vitro, we 
have demonstrated that cumulative base release by the night-
time system is sufficient (≥70 mmol) in case of metabolic 
acidosis (van Gelder, Ligabue, et  al.,  2020). Importantly, 
the capacity of the sorbents to release bicarbonate is highly 
concentration-dependent, an important safety characteristic 
of the device. This concentration dependency implies that 
bicarbonate release is lower at higher plasma (and thus in-
traperitoneal) bicarbonate concentrations, and vice versa. 
Consequently, the risk of metabolic alkalosis and acidosis 
is attenuated. In addition, the effect on plasma bicarbonate 
concentrations can be predicted at the start of each dialysis 
session, allowing the modification of the dialysate prescrip-
tion as required.
The ultrafiltration rate was very variable in the pig. 
Although very high initial intraperitoneal glucose concentra-
tions were prevented during SAPD, no definite conclusions 
could be drawn with regard to the efficacy of ultrafiltration 
with SAPD. During SAPD, the sorbents are loaded with glu-
cose until equilibration is achieved, after which the sorbents 
will start to release glucose. This principle maintains a rather 
constant glucose concentration in the effluent of the system 
and therewith a rather constant osmotic pressure for fluid re-
moval throughout the entire treatment, eliminating the need 
for a separate glucose infusion system. Of note, the sorbents 
are not preloaded with glucose in order to prevent the for-
mation of toxic glucose degradation products during ster-
ilization. Lowering intraperitoneal glucose concentrations 
may prolong PD technique survival, since the exposure of 
the peritoneal membrane to very high glucose concentrations 
causes pathological changes of the peritoneal membrane and 
eventually ultrafiltration failure (Wu et al., 2012). In litera-
ture, adequate ultrafiltration has been observed at relatively 
low maximum intraperitoneal glucose concentrations in 
humans treated with CFPD. Triomed AB (Lund, Sweden) 
treated five patients for eight hours with the Carry Life® 
system for ultrafiltration, a portable ultrafiltration device that 
continuously cycles a small volume of peritoneal dialysate 
via the single-lumen PD catheter, while adding glucose to the 
fluid that is returned to the patient. Intraperitoneal glucose 
concentration was maintained at ~1.3% resulting in a ~3-fold 
higher UFR compared with CAPD (Johansson, Braide, & de 
Leon, 2018). In addition, Freida et al. observed a ~3.5-fold 
increase in ultrafiltration volume per gram of absorbed glu-
cose with CFPD compared with nocturnal intermittent PD in 
five patients (Freida & Issad, 2003), and Raaijmakers et al. 
found a 9-fold higher UFR in six children treated with CFPD 
compared with conventional PD when using PD solutions 
with the same (initial) glucose concentration (Raaijmakers 
et al., 2011).
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Treatment with the SAPD system was well tolerated and 
no serious adverse events occurred that could be related to 
SAPD treatment. Peritonitis (unintentional) was present in 13 
out of 18 experiments. In all cases of peritonitis, a patho-
genic micro-organism and/or increased leukocyte and neu-
trophil count >50% were detected in peritoneal effluent of 
the overnight dwell that was taken prior to SAPD treatment, 
suggesting that peritonitis was not caused by SAPD treatment 
but was most likely due to poor hygienic conditions, inherent 
to pigsties.
This study has limitations. First, the animal model was 
characterized by a low peritoneal transport status and high 
plasma bicarbonate concentration, not representative of the 
human situation. This may account for the limited solute re-
moval, the limited increase in plasma clearance, and MTAC 
as compared with a static dwell and low net base release. 
However, modeling based on in vitro data showed that the 
SAPD system efficiently removes small solutes in case of 
higher solute delivery to the system assuming a ~1.5- to 3.5-
fold increase in MTAC with CFPD in humans at a flow rate of 
~100–200 ml/min (Amerling et al., 2001; Cruz et al., 2001; 
Freida & Issad, 2003; Gotch, 2001; Raaijmakers et al., 2011), 
and may well provide significantly higher solute clearances 
compared with conventional PD. In addition, sufficient base 
release was observed in vitro. Second, ELAR could not be 
determined during SAPD and SPA experiments. Thus, the 
ultrafiltration rate could not be calculated and solutes that 
were reabsorbed by lymphatic drainage were not accounted 
for in the calculation of total mass transport and MTAC. Last, 
a 4-hr static dwell (SPA) was used as a control because this 
is a validated method for the calculation of MTAC, which 
was an important outcome measure as SAPD treatment is 
expected to improve plasma clearance primarily by increas-
ing the MTAC. However, as most PD patients are treated by 
automated PD (APD), this might have underestimated the 
efficacy of the control treatment as frequent exchanges with 
shorter duration may enhance solute removal.
In conclusion, treatment with the SAPD system is safe and 
small solute clearance appeared to be enhanced as compared 
to a static dwell. Furthermore, the SAPD system has the po-
tential to prolong technique survival by avoiding the need for 
very high initial glucose concentrations and to lower peri-
tonitis rates by reducing the number of exchanges and (dis)
connections of the peritoneal catheter. An important ques-
tion remains whether higher clearances improve outcomes. 
Although the ADEMEX trial found that a limited increase 
(~35%) in creatinine clearance did not improve patient sur-
vival (Paniagua et al., 2002), much higher clearances, as may 
be achieved with CFPD, could improve patient outcome. 
Future studies in humans or animal species with higher peri-
toneal transport should elucidate whether our SAPD system 
enhances clearance to a clinically relevant extent as com-
pared to conventional PD and prolongs technique survival.
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